Guidelines Provided for Unilateral Lymphadenopathy After COVID-19 Vaccination
In most clinical settings, ipsilateral UAL after recent COVID-19 vaccination is benign finding; clinical follow-up recommended
In most clinical settings, ipsilateral UAL after recent COVID-19 vaccination is benign finding; clinical follow-up recommended
Biparametric magnetic resonance imaging may offer advantages over PSA testing and ultrasonography by detecting more clinically significant prostate cancers without increasing the number of men advised to undergo prostate biopsies or overdiagnosed with clinically insignificant cancers.
In a study of patients on active surveillance, men with greater periprostatic fat had shorter prostate cancer progression-free survival.
As radiologic tumor size and PI-RADS version 2 score decreased, the degree to which pathologic tumor size is underestimated increased, investigators reported.
Use of computed tomography and bone scans in low-risk prostate cancer cases has been in decline, but doctors continue to order these imaging modalities despite professional guidelines that do not recommend such use.
Ga 68 PSMA-11 PET can detect sites of local recurrence or metastasis in patients with biochemical evidence of recurrent prostate cancer.
In a study, a positive PSMA PET/CT scan was associated with a significant 4.5-fold higher adjusted risk for disease progression.
In a study of men on active surveillance for low-risk prostate cancer, multiparametric magnetic resonance imaging by itself missed about one-fifth of men who had pathologic upgrading on subsequent biopsies.
Comprehensive strategy for safe resumption should consider local COVID-19 statistics, PPE availability.
Increased subspecialization seen across cohorts defined by gender, years in practice, practice size.